Lamond David's Form 4 filing
Quince Therapeutics, Inc. (QNCX) · filed Dec 1, 2023
- Accession no.
- 0001209191-23-057053
- Filed
- Dec 1, 2023
- Trade date
- Nov 29-Dec 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $40.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lamond DavidCIK 0001770790 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | Common Stock | PPurchaseAcquired | +14,378 | $0.98 | +$14,090.44 | 2,193,539 | Indirect | |
| Nov 30, 2023 | Common Stock | PPurchaseAcquired | +14,378 | $0.90 | +$12,940.2 | 2,207,917 | Indirect | |
| Dec 1, 2023 | Common Stock | PPurchaseAcquired | +14,378 | $0.94 | +$13,515.32 | 2,222,295 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.